Jefferies LLC and Cowen & Company, LLC are the joint bookrunners on the deal. No pricing terms have yet been disclosed. News of the filing has come within only a month of the company’s latest financing round of $16 million.
NeuroDerm is a clinical-stage pharmaceutical company developing formulations and new administration methods to treat moderate to severe Parkinson’s disease. The company has developed a line of levodopa/carbidopa product candidates administered through small belt pumps that deliver a continuous, controlled dose of drug. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot.
Read the SEC Filing.
Read about the IPO filing in Hebrew at Globes.